WordCloud Visualization of LPBI’s Top Twelve Articles by Views at All Time and their Research Categories in the Ontology of PharmaceuticalIntelligence.com
July 21, 2020 by Daniel Menzin
WordCloud Visualization of LPBI’s Top Twelve Articles by Views at All Time and their Research Categories in the Ontology of PharmaceuticalIntelligence.com
Curators: Daniel Menzin, Noam Steiner-Tomer, Zach Day, Ofer Markman, PhD, Aviva Lev-Ari, PhD, RN
Article Name Live Link Views All Time Categories of Research Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View? 17,140 Biological Networks , CANCER BIOLOGY & Innovations in Cancer Therapy , Cell Biology , Disease Biology , Genome Biology , Imaging-based Cancer Patient Management , International Global Work in Pharmaceutical , Liver & Digestive Diseases Research , Metabolomics , Molecular Genetics & Pharmaceutical , Nutrition , Pharmaceutical Industry Competitive Intelligence , Pharmaceutical R&D Investment , Population Health Management , Proteomics , Stem Cells for Regenerative Medicine , Technology Transfer: Biotech and Pharmaceutical | Tagged Adenosine triphosphate , ATP , Glycolysis , Hypoxia-inducible factors , Kreb , Lactate dehydrogenase , Mammalian target of rapamycin , Mitochondrion , Warburg Effect Recent comprehensive review on the role of ultrasound in breast cancer management 14,553 Biomarkers & Medical Diagnostics , Health Economics and Outcomes Research , Healthcare costs and reimbursement , Imaging-based Cancer Patient Management , Medical Device Therapies for Altzheimer’s Disease , Medical Devices R&D Investment , Medical Imaging Technology, Image Processing/Computing, MRI, CT, Nuclear Medicine, Ultra Sound | Tagged breast biopsies , breast cancer , breast cancer management , breast cancer screening , breast cyst , breast lesions , breast ultrasound , mammography , MRI , Personalized medicine , PET , support breast cancer , tomosynthesis , yale university school , yale university school of medicine Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) 13,893 Coagulation Therapy and Internal Bleeding , Electrophysiology , FDA Regulatory Affairs , Origins of Cardiovascular Disease , Pharmacotherapy of Cardiovascular Disease | Tagged Academic Medical Center , Amsterdam , Anticoagulant , Apixaban , Dabigatran , Direct thrombin inhibitor , Direct Xa inhibitor , Food and Drug Administration , New England Journal of Medicine , Non-steroidal anti-inflammatory drug , Northeastern University , PRADAXA , Prothrombin time , Rivaroxaban , VTE , Warfarin Paclitaxel vs Abraxane (albumin-bound paclitaxel)cent comprehensive review on the role of ultrasound in breast cancer management 13,878 BioSimilars , CANCER BIOLOGY & Innovations in Cancer Therapy , Disease Biology, Small Molecules in Development of Therapeutic Drugs , Nanotechnology for Drug Delivery , Pharmaceutical Analytics , Pharmaceutical R&D Investment , Regulated Clinical Trials: Design, Methods, Components and IRB related issues | Tagged Abraxane , albumin-bound paclitaxel , breast cancer , clinical studies , FREE paclitaxel , linear PK , non-linear PK , Paclitaxel , Pharmacokinetics , PK , side effects , Taxol
Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications
8,367 Coagulation Therapy and Internal Bleeding , Frontiers in Cardiology and Cardiovascular Disorders , Origins of Cardiovascular Disease , Pharmacotherapy of Cardiovascular Disease , tagged Dabigatran , rivaroxaban and apixaban for stroke prevention in atrial fibrillation
#6
Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care
8,068 Medical Devices R&D Investment , Nitric Oxide in Health and Disease , Technology Transfer: Biotech and Pharmaceutical | Tagged ARDS , Aviva Lev-Ari , Inhaled Nitric Oxide , nitric oxide , prostacyclin , Pulmonary hypertension , Respiratory failure #7Our Team 6,553 LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management #8Mesothelin: An early detection biomarker for cancer (By Jack Andraka) 6,545 Advanced Drug Manufacturing Technology , Bio Instrumentation in Experimental Life Sciences Research , Biological Networks, Gene Regulation and Evolution , Biomarkers & Medical Diagnostics , BioSimilars , CANCER BIOLOGY & Innovations in Cancer Therapy , Cancer Prevention: Research & Programs , Cell Biology, Signaling & Cell Circuits , Disease Biology, Small Molecules in Development of Therapeutic Drugs , Health Economics and Outcomes Research , Medical Devices R&D Investment , Nanotechnology for Drug Delivery , Pharmaceutical R&D Investment , Population Health Management, Genetics & Pharmaceutical , Regulated Clinical Trials: Design, Methods, Components and IRB related issues , Technology Transfer: Biotech and Pharmaceutical | Tagged Blood test , carbon nanotubes , early detection , Mesothelin , Pancreatic cancer Biochemistry of the Coagulation Cascade and Platelet Aggregation: Nitric Oxide: Platelets, Circulatory Disorders, and Coagulation Effects 5,235 Aortic Valve: TAVR, TAVI vs Open Heart Surgery , Biomarkers & Medical Diagnostics , Cell Biology, Signaling & Cell Circuits , Chemical Biology and its relations to Metabolic Disease , Coagulation Therapy and Internal Bleeding , Disease Biology, Small Molecules in Development of Therapeutic Drugs , Metabolomics , Mitral Valve: Repair and Replacement , Nitric Oxide in Health and Disease , Personalized and Precision Medicine & Genomic Research , Pharmaceutical Industry Competitive Intelligence , Pharmacotherapy of Cardiovascular Disease , Population Health Management, Nutrition and Phytochemistry , Proteomics | Tagged anti-inflammatory , anti-TNF , Anticoagulant , Antithrombin , blood flow resistance , cell junctions , cellular adhesion , Coumadin , Endothelial cells , Factor IX and IXa , Factor VII and VIIa , Factor VIII and Factor VIIIa , Factor X and Xa , fibrinogen , fibrinolysis , heparin , Hypoxia-inducible factors , Non-steroidal anti-inflammatory drug , Partial thromboplastin time , Physiology , plasmin , platelet aggregation , platelets , prothrombin , soluble fibrin , subendothelial matrix , Thrombin , thrombomodulin , Thrombus , tissue factor , TNF-a , Von Willebrand factor , WH Seegers #10Interaction of enzymes and hormones 5,173 Cell Biology, Signaling & Cell Circuits , Chemical Biology and its relations to Metabolic Disease , Metabolomics , Population Health Management, Genetics & Pharmaceutical , Population Health Management, Nutrition and Phytochemistry , Reproductive Andrology, Embryology, Genomic Endocrinology, Preimplantation Genetic Diagnosis and Reproductive Genomics | Tagged active compounds , enzyme , hormone , interaction , Metabolism , Therapy Akt inhibition for cancer treatment, where do we stand today? 4,865 CANCER BIOLOGY & Innovations in Cancer Therapy , Cell Biology, Signaling & Cell Circuits | Tagged Cancer research , cancer therapy , Cell Biology , mTOR , NF-κB , PI3K/AKT pathway , PTEN , Signal transduction
#12
The History and Creators of Total Parenteral Nutrition
4,660
Disease Biology , Gastroenterology , Uncategorized | Tagged Amino acids , enteral nutrition , Nutrition , TPN
#1
Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View?
Article #1: WordCloud by DM
#2 Recent comprehensive review on the role of ultrasound in breast cancer management
Article #2: WordCloud by NT
#3 Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran)
Article #3: WordCloud by ZD
#4 Paclitaxel vs Abraxane (albumin-bound paclitaxel)cent comprehensive review on the role of ultrasound in breast cancer management
Article #4: WordCloud by DM
#5
Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications
Article #5: WordCloud by ZD
#6
Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care
Article #6: WordCloud by NT
#7 Our Team
Article #7: WordCloud by DM
Like this: Like Loading...
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Daniel Menzin
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
Rosalind Codrington, PhD
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
zraviv06
zs22
So my suggestion would be actually to focus on the little words, which will give more insight into future targets, as the large words are well known. For example AKT, PI3K cancer is very well studied and dominates the literature. However, looking at some of the lesser ones, siRNA, targeting ,nuclear, complex, breast, targeted can one form into logical sentences which describe new avenues for research?